A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study

• Published in: Journal of neuro-oncology 2013-05, Vol.113 (1), p.127-134
• Main Authors: Hargrave, Darren, Geoerger, Birgit, Frappaz, Didier, Pietsch, Torsten, Gesner, Lyle, Cisar, Laura, Breazna, Aurora, Dorman, Andrew, Cruz-Martinez, Ofelia, Fuster, Jose Luis, Rialland, Xavier, Icher, Céline, Leblond, Pierre, Ashley, David, Perilongo, Giorgio, Elliott, Martin, English, Martin, Clausen, Niels, Grill, Jacques
• Format: Article
• Language: English
• Subjects: Adolescent; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Brain Neoplasms - drug therapy; Brain Neoplasms - pathology; Camptothecin - administration & dosage; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Child; Child, Preschool; Clinical Study; Dacarbazine - administration & dosage; Dacarbazine - adverse effects; Dacarbazine - analogs & derivatives; Female; Glioma - drug therapy; Glioma - pathology; Humans; Male; Medicine; Medicine & Public Health; Neoplasm Grading; Neurology; Oncology; Treatment Outcome
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-013-1098-2

A multicenter, two stage phase II study, investigated irinotecan plus temozolomide in children with newly diagnosed high grade glioma. The primary endpoint was tumor response during a two-cycle treatment window, confirmed by external review committee. Patients received oral temozolomide 100 mg/(m 2  day) (days 1–5) and intravenous irinotecan 10 mg/(m 2  day) (days 1–5 and 8–12) for two 21-day cycles (three cycles for patients exhibiting objective tumor response). Standard treatment was then administered according to local investigator choice. In total 17 patients were enrolled and treated by local investigators. However, central pathology review found three patients did not have a diagnosis of high grade glioma and another four patients did not have evaluable disease according to independent central radiological review. The primary endpoint was based on the first ten evaluable patients as determined by the external review committee. Recruitment was stopped for futility after there were no complete or partial responses during the two-cycle treatment window in the first ten evaluable patients. Five patients had stable disease, and five progressed. Data for secondary endpoints including; time to tumor progression, time to treatment failure, and overall survival is reported. The safety profile of the treatment showed the combination was tolerable with two patients (11.8 %) having grade three nausea, and one (5.9 %) experiencing a grade four neutropenia, leading to permanent discontinuation from adjuvant treatment. Irinotecan plus temozolomide, although well tolerated did not improve outcome over historical controls in this setting.